Condition
High-risk Breast Cancer
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Recruiting1
Not Yet Recruiting1
Terminated1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07366112Phase 2Not Yet Recruiting
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
NCT06970912Phase 2Recruiting
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
NCT05305937Not ApplicableUnknown
Implantation of CEST and CESL MRI Methods for Detection of Breast Tumors
NCT00851110Phase 2TerminatedPrimary
Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors
Showing all 4 trials